Quantcast
Last updated on April 16, 2014 at 13:39 EDT

Latest Personalized medicine Stories

2014-01-16 16:23:38

DUBLIN, January 16, 2014 /PRNewswire/ -- /OFF HOLD OFF HOLD OFF HOLD -- Research and Markets, PIV663770 The following release: "Global Molecular Diagnostics - Technologies, Markets and Companies" is now OFF HOLD. Distribution time: 16 Jan 2014 19:00 GMT Research and Markets (http://www.researchandmarkets.com/research/v524x3/molecular) has announced the addition of a new report "Global Molecular Diagnostics - Technologies, Markets and Companies"...

2014-01-13 23:21:16

This report from BCC Research is an exhaustive study on the cancer profiling and pathways, giving crucial statistics and analysis on the market structure, market size, key technologies, and segments, important trends in technology development, next-generation technologies, major opportunities and market shares of key players and innovative drugs. Wellesley, Mass (PRWEB) January 13, 2014 According to a new technical market research report, Cancer Profiling and Pathways: Technologies and...

2014-01-13 08:28:33

The company's SnapPath® system facilitates personalized medicine MOUNTAIN VIEW, Calif., Jan. 13, 2014 /PRNewswire/ -- Based on its recent analysis of the cancer diagnostics market, Frost & Sullivan recognizes BioMarker Strategies LLC with the 2013 North American Frost & Sullivan Award for Technology Innovation Leadership. BioMarker Strategies has pioneered the development and validation of SnapPath®, a novel platform for live tumor cell processing and testing. This rapid, robust and...

2014-01-13 08:27:55

TARRYTOWN, N.Y., Jan. 13, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has launched a new human genetics initiative via a new wholly owned subsidiary, the Regeneron Genetics Center LLC (RGC). The objective of the RGC is to expand the use of human genetics for defining disease targets and improving the drug development process. The RGC will pursue both large population-based efforts as well as family-based approaches. Central to the...

2014-01-13 04:20:54

GERMANTOWN, Maryland, and HILDEN, Germany, January 13, 2014 /PRNewswire/ -- - Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies - Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine - Automated biofluid-based molecular diagnostics have significant potential to...

2014-01-13 04:20:53

-- Collaboration will focus on enabling detection of known cancer biomarkers in blood plasma NEW YORK, Jan. 13, 2014 /PRNewswire/ -- Exosome Diagnostics today announced an expansion of its strategic collaboration with QIAGEN to develop non-invasive molecular diagnostics for use in detecting and monitoring actionable genetic mutations in lung cancer patients. In contrast with current molecular diagnostics requiring tissue biopsy, the focus will be to enable detection of...

2014-01-12 23:01:11

Personalized Medicine in Oncology Partnering Terms and Agreements report provides understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide. Dallas, Texas (PRWEB) January 12, 2014 The Personalized Medicine in Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the world’s leading...

2014-01-09 12:26:51

NEW YORK, Jan. 9, 2014 /PRNewswire/ -- The New York Genome Center (NYGC) announced that New York State Governor Andrew M. Cuomo proposed in his State of the State address Wednesday afternoon a $105 million partnership between the NYGC and the University at Buffalo's Center for Computational Research, enabling genetic discoveries that will potentially save lives by transforming how health care impacts patients. Governor Cuomo's commitment to vastly enhancing the genomic medicine...

2014-01-08 16:26:14

FDA Study Aimed at Harnessing Immune System to Fight Tumors Now Available at All Five Hospital Sites CHICAGO, Jan. 8, 2014 /PRNewswire-USNewswire/ -- Cancer Treatment Centers of America® (CTCA), a leading provider of innovative cancer care for patients living with complex and advanced-stage disease, is now enrolling patients in an ovarian cancer vaccine clinical trial at all five of its hospital sites. CTCA Western Regional Medical Center (WRMC) in suburban Phoenix, Arizona and...

2014-01-07 23:24:10

Arizona State University and Dublin City University, Dublin, Ireland are joining forces to create the new International School of Biomedical Diagnostics, which will offer the first degree program of its kind. Tempe, AZ (PRWEB) January 07, 2014 Arizona State University (ASU) and Dublin City University (DCU), Dublin, Ireland are joining forces to create the new International School of Biomedical Diagnostics, which will offer the first degree program of its kind. The initiative is at the...